According to Medifast's latest financial reports the company's current revenue (TTM) is $1.37 B. In 2022 the company made a revenue of $1.59 B an increase over the years 2021 revenue that were of $1.52 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.37 B | -14.12% |
2022 | $1.59 B | 4.75% |
2021 | $1.52 B | 63.25% |
2020 | $0.93 B | 30.99% |
2019 | $0.71 B | 42.45% |
2018 | $0.50 B | 66.14% |
2017 | $0.30 B | 9.85% |
2016 | $0.27 B | 0.65% |
2015 | $0.27 B | -10.19% |
2014 | $0.30 B | -14.9% |
2013 | $0.35 B | 0.05% |
2012 | $0.35 B | 19.62% |
2011 | $0.29 B | 15.78% |
2010 | $0.25 B | 55.51% |
2009 | $0.16 B | 57.07% |
2008 | $0.10 B | 25.86% |
2007 | $83.78 M | 13.08% |
2006 | $74.08 M | 84.62% |
2005 | $40.13 M | 46.78% |
2004 | $27.34 M | 7.73% |
2003 | $25.37 M | 105.58% |
2002 | $12.34 M | 145.82% |
2001 | $5.02 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() OPKO Health
OPK | $0.86 B | -36.76% | ๐บ๐ธ USA |
![]() Abeona Therapeutics
ABEO | $3.56 M | -99.74% | ๐บ๐ธ USA |
![]() Bellerophon Therapeutics
BLPH | $5.64 M | -99.59% | ๐บ๐ธ USA |